Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
DL Lacey, WJ Boyle, WS Simonet… - Nature reviews Drug …, 2012 - nature.com
Bone is a complex tissue that provides mechanical support for muscles and joints, protection
for vital organs, a mineral reservoir that is essential for calcium homeostasis, and the …
for vital organs, a mineral reservoir that is essential for calcium homeostasis, and the …
Chronic inflammation in cancer development
G Multhoff, M Molls, J Radons - Frontiers in immunology, 2012 - frontiersin.org
Chronic inflammatory mediators exert pleiotropic effects in the development of cancer. On
the one hand, inflammation favors carcinogenesis, malignant transformation, tumor growth …
the one hand, inflammation favors carcinogenesis, malignant transformation, tumor growth …
MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists
MicroRNA-mediated post-transcriptional regulation plays key roles in stem cell self-renewal
and tumorigenesis. However, the in vivo functions of specific microRNAs in controlling …
and tumorigenesis. However, the in vivo functions of specific microRNAs in controlling …
The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implications
D Vega, NM Maalouf, K Sakhaee - The Journal of Clinical …, 2007 - academic.oup.com
Context: Receptor activator of nuclear factor-κB ligand (RANKL), receptor activator of
nuclear factor-κB (RANK), and osteoprotegerin (OPG) play a central role in bone remodeling …
nuclear factor-κB (RANK), and osteoprotegerin (OPG) play a central role in bone remodeling …
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
Background Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor
of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating …
of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating …
Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy
Recognizing that the transformative effects of immunotherapy are currently limited to a
minority of patients with cancer, research efforts are increasingly focused on expanding and …
minority of patients with cancer, research efforts are increasingly focused on expanding and …
[HTML][HTML] Bone metastasis of breast cancer: molecular mechanisms and therapeutic strategies
L Pang, C Gan, J Xu, Y Jia, J Chai, R Huang, A Li, H Ge… - Cancers, 2022 - mdpi.com
Simple Summary In this review, we present knowledge of the molecular mechanisms and
therapeutic strategies of bone metastasis of breast cancer, particularly the interaction …
therapeutic strategies of bone metastasis of breast cancer, particularly the interaction …
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival
Tumorigenesis can arise from inappropriate activation of developmental genes in mature
tissues. Here, we show that the developmental regulator Six1 is overexpressed in ovarian …
tissues. Here, we show that the developmental regulator Six1 is overexpressed in ovarian …
The RUNX family in breast cancer: relationships with estrogen signaling
NO Chimge, B Frenkel - Oncogene, 2013 - nature.com
The three RUNX family members are lineage specific master regulators, which also have
important, context-dependent roles in carcinogenesis as either tumor suppressors or …
important, context-dependent roles in carcinogenesis as either tumor suppressors or …
Clinical significance of CYLD downregulation in breast cancer
Cylindromatosis (CYLD) is a tumor suppressor gene that is mutated in familial
cylindromatosis, a rare autosomal dominant disorder associated with numerous benign skin …
cylindromatosis, a rare autosomal dominant disorder associated with numerous benign skin …